Entrada Therapeutics Inc
NASDAQ:TRDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
US |
|
Officina Stellare SpA
MIL:OS
|
IT |
|
Alamo Group Inc
NYSE:ALG
|
US |
Intrinsic Value
The intrinsic value of Entrada Therapeutics Inc (TRDA) under the Base Case is 1.82 USD per share.
Compared with the current market price of 4.78 USD, the stock appears
Overvalued by 62% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Entrada Therapeutics Does
Entrada Therapeutics is a biotechnology company focused on getting medicines into cells, especially into hard-to-reach tissues like muscle. Its core technology is a delivery platform that helps large drug molecules, such as oligonucleotides and proteins, cross into cells where many diseases actually start. The company is mainly developing these medicines for genetic and neuromuscular diseases, where precise delivery can make a treatment work.
- Headquarters
- United States of America US
- Employees
- 152
- IPO date
- Oct 29, 2021
Earnings Waterfall
Entrada Therapeutics Inc
The intrinsic value for Entrada Therapeutics Inc (TRDA) under the Base Case is 1.82 USD.
Compared with the current market price of 4.78 USD, the stock appears Overvalued by 62% .